GREENWICH LIFESCIENCES INC

NASDAQ: GLSI (Greenwich LifeSciences, Inc.)

Last update: 1 hour ago

17.71

3.95 (28.71%)

Previous Close 13.76
Volume 855,441
Price / Book 70.35
52 Weeks Range
7.78 (-56%) — 34.10 (92%)
Diluted EPS (TTM) -1.27
Current Ratio (MRQ) 1.91
Operating Cash Flow (TTM) -7.32 M
Levered Free Cash Flow (TTM) -1.22 M
Return on Assets (TTM) -253.55%
Return on Equity (TTM) -515.27%

AIStockmoo Score

-2.4
Value 30% -3.9
From our AI Insight report's view of expected return against risk. info NA
Relative Valuation info NA
Implied Growth info NA
Valuation History info NA
Weak profitability. Ample short-term liquidity. Negative cash flow. info
Earns below its cost of capital. Returns on capital falling. info
Timing 30% -2.2
From our AI technical analysis of the chart. info NA
Uptrend over the past year. Far below its 52-week high. info
Candle Patterns info NA
Trend for Your Holding Period info NA
Sentiment 20% 0.0
No recent price targets, so based on how targets have been revised. info
News Mood info NA
Smart Money 20% 0.2
Insider Activity info NA
Institutions net +0.15% of shares in their latest 13F filings: 35 holders increased, 18 decreased (quarter to 30 Sep 2026). info
Short interest -5.0% from 31 Aug to 30 Oct 2026, 12.5 days to cover (FINRA). info
Market and sector conditions are poor.
Market environment cautious. info
Sector lagging the market.
The pillars agree, so the score is strengthened.
Not in score
Price is low against its 52-week average. Down over 5 years. info
Short-term trend up, medium and long-term down. Short-term momentum falling. info
Price is between support and resistance. Levels trending up. info
Final Score -2.42

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Mixed Bullish
Biotechnology (Global) Mixed Bullish
Stock Greenwich LifeSciences, Inc. Mixed Bullish

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
GLSI - - - 70.35
GLTO 2 B - - -
IPA 96 M - - 5.98
ACIU - - - 6.56
DNLI - - - 3.24
GHRS - - - 3.65

Select this tab to load the latest available analysis.

Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual’s immune system to selectively attack cancer cells to inhibit the spread of cancer.

Sector Healthcare
Industry Biotechnology
Investment Style Small Value
% Held by Insiders 52.30%
% Held by Institutions 9.47%

No data within this time range.

No data within this time range.

Institutions

Institutional ownership: 13.79%

Positions Holders Shares
Increased 35 189,628
Decreased 18 137,114
New 4 18,060
Sold out 7 48,039

SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.

Short Interest

Settlement Shares Days to cover
30 Oct 2026 1,578,166 12.5
15 Oct 2026 1,552,366 10.7
30 Sep 2026 1,580,950 11.4
15 Sep 2026 1,631,150 19.8
31 Aug 2026 1,660,969 11.4
14 Aug 2026 1,593,720 13.3

FINRA short interest via Nasdaq, reported twice a month.

0 Positive 0 Negative 2 Neutral
Date Type Details
17 Nov 2026 Yahoo Finance Greenwich LifeSciences Gears Up For Two Breast Cancer Vaccine Presentations — Retail Says ‘Peptide Vaccine Works’ After SLS Trial Success
Greenwich said two research abstracts related to its experimental breast cancer drug were accepted for the San Antonio Breast Cancer Symposium, scheduled for December 8 to 11…
17 Nov 2026 Yahoo Finance Greenwich LifeSciences Announces Acceptance of Abstracts at SABCS 2026
STAFFORD, Texas, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast…
15 Sep 2026 Yahoo Finance 3 Clinical-Stage Cancer Stocks With Pristine Balance Sheets
Rising rates raise the bar for risky science. Meet three clinical-stage cancer stocks with pristine, debt-free balance sheets, plus the screener that surfaces the rest.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria